Abstract
Antibiotics are the therapeutic agents most often associated with hepatotoxicity. However, this is mainly due to the widespread prescription of these drugs. The relative risk of antibiotic-related hepatotoxicity is low. Causality assessment of suspected drug-induced liver injury (DILI) related to antibiotics can be difficult, particularly because some cases occur long after the drug has been stopped. Among the penicillins, amoxicillin clavulanate is the most associated with hepatotoxicity and is the most frequent cause of DILI-related hospitalisations. Flucloxacillin ranks as the second highest cause of DILI in many countries. The severity of antibiotic-induced DILI varies widely, with the hepatitis-like (hepatocellular) damage tending to be more severe that than cholestatic/mixed type. The pattern is strongly influenced by age. Recently telithromycin (a new generation macrolide) has been linked with DILI, with a typical pattern, which includes abrupt commencement of fever, abdominal pain, jaundice and, in some cases, ascites. Antibiotic-induced DILI appears, in most instances, to be idiosyncratic. Genetic-association studies have recently identified genotypes related to flucloxacillin and possibly to amoxicillin-clavulanate hepatotoxicity.
Keywords: Drug-induced liver injury, antibiotics, fulminant liver failure, causality assessment, amoxicillin-clavulanate, genetic factors
Current Drug Safety
Title: Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment
Volume: 5 Issue: 3
Author(s): Mercedes Robles, Elena Toscano, Judith Cotta, Ma Isabel Lucena and Raul J. Andrade
Affiliation:
Keywords: Drug-induced liver injury, antibiotics, fulminant liver failure, causality assessment, amoxicillin-clavulanate, genetic factors
Abstract: Antibiotics are the therapeutic agents most often associated with hepatotoxicity. However, this is mainly due to the widespread prescription of these drugs. The relative risk of antibiotic-related hepatotoxicity is low. Causality assessment of suspected drug-induced liver injury (DILI) related to antibiotics can be difficult, particularly because some cases occur long after the drug has been stopped. Among the penicillins, amoxicillin clavulanate is the most associated with hepatotoxicity and is the most frequent cause of DILI-related hospitalisations. Flucloxacillin ranks as the second highest cause of DILI in many countries. The severity of antibiotic-induced DILI varies widely, with the hepatitis-like (hepatocellular) damage tending to be more severe that than cholestatic/mixed type. The pattern is strongly influenced by age. Recently telithromycin (a new generation macrolide) has been linked with DILI, with a typical pattern, which includes abrupt commencement of fever, abdominal pain, jaundice and, in some cases, ascites. Antibiotic-induced DILI appears, in most instances, to be idiosyncratic. Genetic-association studies have recently identified genotypes related to flucloxacillin and possibly to amoxicillin-clavulanate hepatotoxicity.
Export Options
About this article
Cite this article as:
Robles Mercedes, Toscano Elena, Cotta Judith, Isabel Lucena Ma and J. Andrade Raul, Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698307
DOI https://dx.doi.org/10.2174/157488610791698307 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Inhibitory Activity for Serine Protease Inhibitor Kazal Type-3 (Spink3) on Human Recombinant Kallikreins
Protein & Peptide Letters Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin Withdrawal Leads to the Destruction of Young Red Cells at the Endothelial-Macrophage Interface
Current Pharmaceutical Design Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP
Current Pharmaceutical Analysis The Potential Protective Effect of Orange Peel and Selenium against 17β-Estradiol- Induced Chronic Non-Bacterial Prostatitis in Rats
Anti-Cancer Agents in Medicinal Chemistry Modes of Action of Arjunolic Acid and Derivatives on Trypanosoma cruzi Cells
Current Topics in Medicinal Chemistry The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells
Current Drug Delivery Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Mouse Prostate Proteome Changes Induced by Oral Pentagalloylglucose Treatment Suggest Targets for Cancer Chemoprevention
Current Cancer Drug Targets Identification of Novel Key Targets and Candidate Drugs in Oral Squamous Cell Carcinoma
Current Bioinformatics A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design A New Approach for Predicting the Value of Gene Expression: Two-way Collaborative Filtering
Current Bioinformatics Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design